北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia
作者: Huang, Xiao-Jun; Xu, Lan-Ping; Liu, Kai-Yan; Liu, Dai-Hong; Chen, Huan; Liu, Yan-Rong; Chen, Yu-Hong; Han, Wei; Wang, Yu
关键词: HLA-matched ; Blood and marrow transplantation ; Chronic myeloid leukemia ; BCR-ABL
刊名: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
发表日期: 2011-05-01
DOI: 10.1016/j.bbmt.2010.07.023
卷: 17, 期:5, 页:649-656
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology ; Immunology ; Transplantation
研究领域[WOS]: Hematology ; Immunology ; Transplantation
关键词[WOS]: STEM-CELL TRANSPLANTATION ; REDUCED-INTENSITY TRANSPLANTATION ; COMPLETE CYTOGENETIC RESPONSE ; CHRONIC MYELOGENOUS LEUKEMIA ; TERM-FOLLOW-UP ; LYMPHOCYTE INFUSION ; IMATINIB MESYLATE ; WORKING PARTY ; RELAPSE ; CML
英文摘要:

The aim of this study was to determine the effect of individualized intervention guided by BCR-ABL transcript levels after hematopoietic stem cell transplantation (HSCT) on relapse and leukemia-free survival (LFS) of patients with chronic myelogenous leukemia (CML). Eighty-four consecutive patients who received HLA-identical sibling HSCT were enrolled. The patients were conditioned with a modified busulfan and cyclophosphamide regimen, and received stem cells from a HLA-identical sibling donor. Patients were identified as high risk of relapse based on serial monitoring of post-HSCT BCR-ABL transcript levels, and patients in the high-risk group were given individualized intervention. Interventions included immunosuppressant withdrawal, modified donor lymphocyte infusion, and imatinib mesylate. Engraftment was successful in all patients. Twenty-eight patients were categorized as high risk because of higher post-HSCT BCR-ABL transcript levels and received intervention. The 56 low-risk patients received no intervention. Twenty-five high-risk patients achieved complete molecular remission at a median of 49 days (range: 18-232 days) after intervention. Two high-risk patients and 1 low-risk patient ultimately relapsed, the 4-year relapse rate was 3.9% +/- 4.4%. Overall 4-year survival was 89.0% +/- 7% and the 4-year LFS was 89.2% +/- 6.8%. All surviving patients remains in complete molecular remission after a median of 1481(1040-1794) days follow-up. Individualized intervention based on the post-HSCT BCR-ABL transcript level can decrease relapse and increase LFS of patients with CML after HLA-identical sibling HSCT. Biol Blood Marrow Transplant 17: 649-656 (2011) (C) 2011 American Society fir Blood and Marrow Transplantation

语种: 英语
所属项目编号: 30725038 ; IRT0702 ; 2006AA02Z4A0
项目资助者: National Outstanding Yong Scientists&prime ; Foundation of China ; Program for Innovative Research Team in University ; HI-Tech Research Development Program of China 863
WOS记录号: WOS:000290061500007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/62980
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China

Recommended Citation:
Huang, Xiao-Jun,Xu, Lan-Ping,Liu, Kai-Yan,et al. Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2011,17(5):649-656.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Huang, Xiao-Jun]'s Articles
[Xu, Lan-Ping]'s Articles
[Liu, Kai-Yan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Huang, Xiao-Jun]‘s Articles
[Xu, Lan-Ping]‘s Articles
[Liu, Kai-Yan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace